Recombinant Mouse FGFR3 alpha (IIIb) Fc Chimera Protein, CF

Catalog #: 9089-FR Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
9089-FR-050

Recombinant Mouse FGFR3 alpha (IIIb) Fc Chimera Protein Bioactivity

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Mouse FGFR3 alpha (IIIb) Fc Chimera Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to inhibit FGF acidic-dependent proliferation of BaF3 mouse pro‑B cells transfected with human FGF R3 (IIIc). The ED₅₀ for this effect is 0.2-1.2 μg/mL.

Source

Mouse myeloma cell line, NS0-derived mouse FGF R3 protein

Mouse FGF R3 (IIIb) (Ala33-Tyr369) Accession # NP_001156689	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Accession #

NP_001156689

N-terminal Sequence
Analysis

Ala33

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

63 kDa

SDS-PAGE

83-101 kDa, reducing conditions

Product Datasheets

9089-FR

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

9089-FR

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Mouse FGF R3 (IIIb) Fc Chimera (Catalog # 9089-FR) inhibits Recombinant Mouse FGF acidic (Catalog # 4686-FA)-dependent proliferation of Human FGF R3 (IIIc) transfected BaF3 mouse pro‑B cells. The ED₅₀ for this effect is 0.2-1.2 μg/mL.

Reconstitution Calculator

Background: FGFR3

Fibroblast growth factor receptor 3 (FGF R3), also known as CEK2 and CD333, is an approximately 120 kDa transmembrane receptor tyrosine kinase that plays a role in skeletal development and tumorigenesis (1). Mature mouse FGF R3 (IIIc) consists of a 349 amino acid (aa) extracellular domain (ECD) with three Ig-like domains, a 21 aa transmembrane segment, and a 411 aa cytoplasmic domain that contains the tyrosine kinase domain (2). Alternative splicing generates an additional isoform (IIIb) with a substitution in the third Ig-like domain (3). Within the ECD, mouse FGF R3 (IIIb) shares 91% and 98% aa sequence identity with comparable isoforms of human and rat FGF R3, respectively. The FGF R3 (IIIb) triggers cell proliferation in response to FGF acidic and FGF-9, while FGF R3 (IIIc) shows a wider selectivity that includes FGF acidic, FGF basic, FGF-4, -8, -9, -17, -18, -19, and -20 (4, 5). Ligand binding induces receptor dimerization and acitvation of the tyrosine kinase domain (1). FGF mediated activation of FGF R3 is dependent on the presence of heparan sulfate proteoglycans (6). FGF R3 functions as a negative regulator of endochondral bone growth, and FGF R3 mutations are associated with chondrodysplasia in humans (7, 8). In addition, the development of many cancers is associated with mutations or dysregulation of FGF R3 which can result in constitutive receptor activation (1).

References